To investigate the dynamics of transcriptional responses of IBD patients after therapeutic exposure to a TNF antagonist, we analyzed longitudinal whole blood transcriptomic data before (baseline) and at up to 6 time points after the introduction of infliximab therapy in the discovery cohort (Fig. 1A). This evidence concerns the gene TNF and inflammatory bowel disease.